Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05309187
Title Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immune-Onc Therapeutics Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
USC-Norris Comprehensive Cancer Center (119) Los Angeles California 90033 United States Details
University of Florida (125) Gainesville Florida 32610-0278 United States Details
Northwestern University - Feinberg School of Medicine (133) Chicago Illinois 60611 United States Details
Indiana University (123) Indianapolis Indiana 46202 United States Details
Tisch Mount Sinai (124) New York New York 10029 United States Details
Carolina BioOncology (102) Huntsville North Carolina 28078 United States Details
Sarah Cannon Research Institute/Tennessee Oncology (122) Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research (108) Dallas Texas 75251 United States Details
MD Anderson Cancer Center (101) Houston Texas 77030 United States Details
NEXT Oncology Virginia (121) Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field